UPLIFT (ENGOT-OV67/GOG-3048): Results from the Phase II Trial of Upifitamab Rilsodotin (upri; XMT-1536), a NaPi2b-directed Dolaflexin Antibody-Drug Conjugate in Platinum-Resistant Ovarian Cancer
GYNECOLOGIC ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined